Saloomeh Saati, Ronalee Lo, Po-Ying Li, Ellis Meng, Rohit Varma, Mark S Humayun
{"title":"Mini drug pump for ophthalmic use.","authors":"Saloomeh Saati, Ronalee Lo, Po-Ying Li, Ellis Meng, Rohit Varma, Mark S Humayun","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the feasibility of developing a novel mini drug pump for ophthalmic use.</p><p><strong>Methods: </strong>Using principles of microelectromechanical systems engineering, a mini drug pump was fabricated. The pumping mechanism is based on electrolysis, and the pump includes a drug refill port as well as a check valve to control drug delivery. Drug pumps were tested first on the benchtop and then after implantation in rabbits. For the latter, we implanted 4 elliptical (9.9 x 7.7 x 1.8 mm) non-electrically active pumps into 4 rabbits. The procedure is similar to implantation of a glaucoma seton. To determine the ability to refill and also the patency of the cannula, at intervals of 4 to 6 weeks after implantation, we accessed the drug reservoir with a transconjunctival needle and delivered approximately as low as 1 microL of trypan blue solution (0.06%) into the anterior chamber. Animals were followed up by slit-lamp examination, photography, and fluorescein angiography.</p><p><strong>Results: </strong>Benchtop testing showed 2.0 microL/min delivery when using 0.4 mW of power for electrolysis. One-way valves showed reliable opening pressures of 470 mm Hg. All implanted devices refilled at 4- to 6-week intervals for 4 to 6 months. No infection was seen. No devices extruded. No filtering bleb formed over the implant.</p><p><strong>Conclusions: </strong>A prototype ocular mini drug pump was built, implanted, and refilled. Such a platform needs more testing to determine the long-term biocompatibility of an electrically controlled implanted pump. Testing with various pharmacologic agents is needed to determine its ultimate potential for ophthalmic use.</p>","PeriodicalId":23166,"journal":{"name":"Transactions of the American Ophthalmological Society","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814560/pdf/1545-6110_v107_p060.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transactions of the American Ophthalmological Society","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To evaluate the feasibility of developing a novel mini drug pump for ophthalmic use.
Methods: Using principles of microelectromechanical systems engineering, a mini drug pump was fabricated. The pumping mechanism is based on electrolysis, and the pump includes a drug refill port as well as a check valve to control drug delivery. Drug pumps were tested first on the benchtop and then after implantation in rabbits. For the latter, we implanted 4 elliptical (9.9 x 7.7 x 1.8 mm) non-electrically active pumps into 4 rabbits. The procedure is similar to implantation of a glaucoma seton. To determine the ability to refill and also the patency of the cannula, at intervals of 4 to 6 weeks after implantation, we accessed the drug reservoir with a transconjunctival needle and delivered approximately as low as 1 microL of trypan blue solution (0.06%) into the anterior chamber. Animals were followed up by slit-lamp examination, photography, and fluorescein angiography.
Results: Benchtop testing showed 2.0 microL/min delivery when using 0.4 mW of power for electrolysis. One-way valves showed reliable opening pressures of 470 mm Hg. All implanted devices refilled at 4- to 6-week intervals for 4 to 6 months. No infection was seen. No devices extruded. No filtering bleb formed over the implant.
Conclusions: A prototype ocular mini drug pump was built, implanted, and refilled. Such a platform needs more testing to determine the long-term biocompatibility of an electrically controlled implanted pump. Testing with various pharmacologic agents is needed to determine its ultimate potential for ophthalmic use.
目的:评价研制一种新型眼科微型药物泵的可行性。方法:利用微机电系统工程原理,制作微型药物泵。所述泵送机构基于电解,所述泵包括药物补给口以及控制药物输送的止回阀。药物泵首先在实验台上进行测试,然后在植入兔子体内后进行测试。对于后者,我们将4个椭圆形(9.9 x 7.7 x 1.8 mm)非电活性泵植入4只兔子体内。手术过程类似于青光眼植入。为了确定重新填充的能力和插管的通畅程度,在植入后4至6周的间隔时间内,我们使用经结膜针进入药物储存库,并向前房注入大约低至1微升的台泮蓝溶液(0.06%)。动物随访采用裂隙灯检查、摄影和荧光素血管造影。结果:台式测试显示,电解功率为0.4 mW时,输出量为2.0 microL/min。单向阀显示可靠的开启压力为470毫米汞柱。所有植入的装置每隔4至6周重新填充一次,持续4至6个月。未见感染。没有挤压设备。植入物上方未形成滤泡。结论:建立了一个眼部微型药物泵的原型,植入并重新填充。这样的平台需要更多的测试来确定电控植入泵的长期生物相容性。需要用各种药理学试剂进行试验,以确定其在眼科应用的最终潜力。